Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Xinling Pharmaceutical logo — Pioneering advanced transdermal patches and oral films for e...

Xinling Pharmaceutical

Pioneering advanced transdermal patches and oral films for enhanced efficacy and patient comfort.

Founded 2019 Seed Total: $100.00M Pharmaceutical

General Information

Company Name Xinling Pharmaceutical
Founded Year 2019
Industries Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Xinling Pharmaceutical. To contact Xinling Pharmaceutical, visit novastagepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Xinling Pharmaceutical compare?

A PDF of Xinling Pharmaceutical and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Xinling Pharmaceutical soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Xinling Pharmaceutical

Xinling Pharmaceutical is a pharmaceutical startup founded in 2019 that specializes in developing advanced formulation technologies for transdermal patches and oral films. The company's slogan, "Pioneering advanced transdermal patches and oral films for enhanced efficacy and patient comfort," reflects its dedication to innovation in drug delivery methods. Xinling Pharmaceutical's drug products in these forms are designed to offer lower toxicity, increased efficacy, and enhanced patient compliance compared to traditional dosage methods. The startup recently received a CNY100.00M Seed Round investment on 18 March 2022, with funding from Fuho Capital and China Science and Technology Innovation. This investment is a testament to the potential investors see in Xinling Pharmaceutical's innovative approach to drug delivery within the pharmaceutical industry.

Business keywords: transdermal patches, oral films, formulation technologies, drug products, toxicity reduction, increased efficacy, patient compliance, advanced formulations, pharmaceutical research, advanced drug delivery, transdermal drug delivery, oral drug delivery

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round CNY100.00M 2
Fuho Capital
Fuho Capital, China Science and Technology Innovation
18 Mar 2022

Xinling Pharmaceutical Alternatives & Competitors

View All Alternatives
Xinling Pharmaceutical vs
ARx, LLC
ARx, LLC United States

Patient-friendly, alternative drug delivery systems through Oral Thin Films and Transdermal Patches.

55 employees
Health Care, Manufacturing
Xinling Pharmaceutical vs
LTS Lohmann Therapie-Systeme AG
LTS Lohmann Therapie-Systeme AG Germany

We CARE. We CREATE. We DELIVER.

Grant
326 employees
Biotechnology, Health Care
Xinling Pharmaceutical vs
Therakind Limited
Therakind Limited United Kingdom

Enhancing access to safe and effective specialized medicines for children and underserved patient gr...

Venture round
11 employees
Health Care, Pharmaceutical
View all alternatives

FAQ About Xinling Pharmaceutical

Pioneering advanced transdermal patches and oral films for enhanced efficacy and patient comfort.
Xinling Pharmaceutical was founded in 2019.
Xinling Pharmaceutical operates in Pharmaceutical. Its work centres on transdermal patches, oral films, formulation technologies and drug products.
Xinling Pharmaceutical has completed 1 funding round, raising a total of $100.00M. The latest funding stage is Seed.
Top alternatives and competitors to Xinling Pharmaceutical include ARx, LLC, LTS Lohmann Therapie-Systeme AG, Therakind Limited, CURE Pharmaceutical , Corium International. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xinling Pharmaceutical and ARx, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Xinling Pharmaceutical, https://bouncewatch.com/company/xinling-pharmaceutical, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes